Sequence: Acetyl-KLULKLULKULKAULKLU-GC-[cyclo(-Arg-Gly-Asp-D-Phe-Cys-)]-NH2
| Experiment Id | EXP002099 |
|---|---|
| Paper | α-Aminoisobutyric Acid-Containing Amphipathic Helical Peptide–Cyclic RGD Conjugation as a Potential |
| Peptide | MAP(Aib)-cRGD |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 100–2000 nM |
| Rna Concentration | 20 nM |
| Mixing Ratio | 50:1 |
| Formulation Format | noncovalent peptide–miRNA complex |
| Formulation Components | MAP(Aib)-cRGD + miRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | WiDr; DLD-1; PBMC |
| Animal Model | |
| Administration Route | |
| Output Type | gene regulation / anticancer phenotype |
| Output Value | Target gene suppression; apoptosis; growth inhibition |
| Output Units | |
| Output Notes | Functional MIR145-5p delivery with target gene knockdown and anticancer effects in CRC cells |
| Toxicity Notes | Low toxicity in PBMC at working concentrations |
| Curation Notes |